All News

Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year
January 22, 2021

The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.

Cabozantinib Plus Nivolumab Is Granted Full Approval for Frontline RCC Indication
January 22, 2021

The FDA granted approval to the combination use of cabozantinib plus nivolumab ahead of its February PDUFA date as therapy for the first-line treatment of patients with advanced renal cell carcinoma.

Promising Efficacy Data for Heavily Pretreated CLL/SLL Indicate Potential Benefit for Liso-cel Combination With Ibrutinib
January 22, 2021

Findings from a phase 1/2 trial indicate that lisocabtagene maraleucel plus ibrutinib may represent a viable treatment option for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma and high-risk disease features.